Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
The Food and Drug Administration (FDA) has granted de novo authorization for the artificial intelligence (AI) powered software Clairity Breast, which can offer five-year assessment of breast cancer risk based on screening mammograms alone.
Validated on more than 77,000 mammograms from multiple hospital-based and free-standing facilities, the Clairity Breast software provides AI assessment of pixel-level imaging data to enhance personalized risk stratification, according to Clairity, the developer of the software.
Could the AI-powered Clairity Breast software be a game-changer for mammogram assessment? The software, which recently garnered FDA de novo authorization, can reportedly predict five-year breast cancer risk based on screening mammography alone. (Image courtesy of Adobe Stock.)
Emphasizing the challenges of traditional breast cancer risk screening protocols due to a lack of diversity in training cohorts and a lack of prior family history with the disease in 85 percent of women diagnosed with breast cancer, Clairity said the Clairity Breast offers game-changing potential for facilitating early detection.
“For more than 60 years, mammograms have saved lives by detecting early-stage cancers. Now advancements in AI and computer vision can uncover hidden clues in the mammograms — invisible to the human eye — to help predict future risk,” said Connie Lehman, M.D., a professor at Harvard Medical School and the founder of Clairity. “By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere.”
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
